PTK/ZK (Novartis).

Joachim, Drevs

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2004

Data sources: Europe PubMed Central

PTK/ZK (Novartis).

descriptionPublicationkeyboard_double_arrow_right Article 04 May 2004 English Journal:IDrugs : the investigational drugs journal, volume 6 (issn: 1369-7056,

Copyright policy )

Authors: Joachim, Drevs;

pmid: 12917775

PTK/ZK (Novartis).

- Summary
- Subjects
- Metrics

Abstract

PTK/ZK, a VEGF receptor tyrosine kinase inhibitor, is under development by Novartis AG and Schering AG as an inhibitor of angiogenesis for the potential treatment of various cancers.

Keywords

Clinical Trials, Phase I as Topic, Pyridines, Angiogenesis Inhibitors, Antineoplastic Agents, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Receptors, Vascular Endothelial Growth Factor, Clinical Trials, Phase III as Topic, Animals, Humans, Phthalazines

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	7
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%